Pegaptanib (Macugen®) is a 50 kDa VEGF-A targeted RNA aptamer, which has been approved for angiogenic age-related macular degeneration in December 2004, leading to good tolerability and negligible local adverse effects of AMD patients through intravitreous injections (Table 1).390. The gene discussed is VEGFA; the disease is age-related macular degeneration.